

## INDEX

Note: RLS is the abbreviation for Restless Legs Syndrome;

WED is for Willis-Ekbom Disease.

Page numbers in *italics* refer to figures.

Page numbers followed by a t indicate tables.

- Abbreviations, 13t, 325-327
- Actigraphy, PLM measurement by, 44, 118
- Acupuncture/acupressure, 147, 148
- Adenosine receptor medications, 304
- ADHD (attention deficit hyperactivity disorder), 65, 266-267, 287-288
- African Americans, prevalence of RLS in, 55
- Age
- PLMS and, 42, 42
  - as risk factor for RLS, 55t, 56
- Airplane flights
- difficulties due to RLS, 26, 101
  - medications for, 237
  - mental alerting activities, benefits of, 145
- Akathisia, 29-31, 31t
- caused by psychiatric medications, 137, 289
  - as mimic of RLS, 29-31, 31t, 35t
- Akpinar, Sevket, 45, 155, 185, 200
- Alcohol, 135-136, 181
- abstinence from, 233
- Algorithms for RLS management, 231-259
- daily RLS, 240
  - intermittent RLS, 232
  - refractory RLS, 247
- $\alpha 2\delta$  ligands, 156t, 189-195
- action mechanism, 189
  - in combination therapy, 253-254
  - FDA-approved for RLS (gabapentin enacarbil), 189-195
  - FDA-unapproved, but with efficacy for RLS, 195-198
  - as first-line treatment, 243, 304
  - gabapentin enacarbil (Horizant), 189-195, 243
    - not interchangeable with gabapentin, 190
  - improvement of insomnia with, 127
  - pregnancy warning for, 127
- $\alpha 2\delta$  ligands (*continued*)
- side effects, 195, 251-252
  - for treatment of RLS augmentation, 183
  - use for chronic/daily RLS, 240, 241t
  - use for comorbid anxiety disorder, 241t
  - use for intermittent RLS, 232, 233t, 237
  - use for painful RLS, 241t
  - use for refractory RLS, 247, 248
  - use for sleep disturbance, 241t
  - worsening of depressive symptoms, 127
  - worsening of pain syndromes, 127
- See also *Anticonvulsants; Gabapentin enacarbil.*
- Alprazolam, 210-212, 211t
- pregnancy risk category, 269t
- Alternative medical systems, 147
- Alternative medications (RLS-friendly), 139, 140t, 215, 290t
- Amantadine, 215
- American Academy of Sleep Medicine (AASM), 319
- Anemia
- as causal factor in RLS, 58-59, 69
  - laboratory evaluation for, 116
- Anticonvulsants, 156t, 188-200, 188t, 293
- $\alpha 2\delta$  ligands, 156t, 189-195
  - FDA approved for RLS (gabapentin enacarbil), 157, 188t
  - gabapentin, 156t, 195-197
    - not FDA approved for RLS, 195
  - gabapentin enacarbil (Horizant), 157, 188t, 189-195
    - bioavailability, 190
    - FDA approved for RLS, 189
    - not interchangeable with gabapentin, 190
  - not FDA approved for RLS, but with efficacy for RLS symptoms, 195-200
  - other anticonvulsants, 198-200
    - carbamazepine, 188t, 198
    - lamotrigine, 188t, 199
    - levetiracetam, 188t, 199
  - off-label use for RLS symptoms, 198-200
  - oxcarbazepine, 188t, 199
  - topiramate, 188t, 199
  - valproic acid, 188t, 199-200
- pregabalin (Lyrica), 156t, 197-198

## Anemia (*continued*)

- pregnancy and breast-feeding concerns, 268-269, 269t
- side effects, 188-189
  - sedation and dizziness, 188, 193, 196
  - skin rash, 189
  - suicide and ideation, 188
- use for painful RLS symptoms, 189

See also *specific agents*.

## Antidepressants, 291-293

- alternatives for, 290t
- combined with caffeine, 135
- PLM increased by, 43t
- RLS improvement with, 137
- RLS provocation/worsening with, 58, 95, 137
- selective serotonin reuptake inhibitors (SSRIs), 135, 137, 291-292
- serotonin-norepinephrine reuptake inhibitors (SNRIs), 291-292
- tricyclic antidepressants (TCAs), 137, 291-292

## Antidizzy medications, 138

- alternatives for, 140t

## Antiemetic medications, 138

- alternatives for, 140t
- exacerbation of RLS by, 289-291

## Antihistamines, 137-138, 294

- alternatives for, 140t
- worsening of RLS with, 137-138, 181, 294

## Antinausea medications, 138

- alternatives for, 140t

## Anxiety

- anticonvulsant medications and, 189
- comorbidity with RLS, 17, 58, 127
  - $\alpha\delta$  ligands for, 241t
- job-related consequences of, 100
- medications for, worsening of RLS by, 95
- as mimic of RLS, 31t, 35t
- in RLS patients, 17, 94-95, 283, 284-287

## Apnea. See *sleep apnea*

## Apomorphine, 159t, 185

- use during surgery, 272

## Approaching the RLS patient. See *management of RLS*.

## Aripiprazole, 290t, 291

## Arms, periodic movements in, 23-25, 38, 40-41

## Arthritic conditions

- as RLS mimics, 32, 32t, 35t
  - secondary RLS due to, 59
  - specialists for (rheumatologists), 303t
- ## Attention deficit hyperactivity disorder (ADHD), 65, 266-267, 287-288

## Augmentation, 173, 173t, 176-183, 252, 302

- assessment, purpose of, 113
- Augmentation Severity Rating Scale, 112-113, 310-315
- diagnosis and evaluation of, 177, 179-181
  - diagnostic criteria, 173t, 178
  - differential diagnosis, 180-181, 180t
- family history and, 179
- intermittent medication use for avoidance of, 156, 175, 177
- L-dopa and, 156, 176-179
- prevalence of, 177
- prevention of, 183
- in refractory RLS, 131, 252
- treatment of, 181-183, 252

## Autoimmune factors, screening for, 116

## B<sub>12</sub>, vitamin, deficiency, 55t

## “Bag of tricks” for RLS management, 233-234

## Bandolier web site, 319

## Basal ganglia, involvement in RLS, 76t

## Bedtime RLS, 27-29, 236-237

## Benserazide, L-dopa combined with, 173-174, 236

## Benzodiazepines, 139, 210-213, 211t

- alprazolam, 210-212, 211t
  - clonazepam, 209, 211t, 212-213
  - concerns for RLS treatment, 294
  - cross-tolerance among, 256
  - placebo effect and, 209
  - pregnancy and breast-feeding concerns, 269, 269t
  - temazepam, 211t, 213
  - triazolam, 211t, 213
  - use for insomnia, 294
  - use for intermittent RLS, 232
  - use for periodic limb movement disorder (PLMD), 274
  - use for uremic RLS, 265
- ## Berger’s disease, as RLS mimic, 32t

Biologically based therapies, 147  
 Bipolar disorders, medications for, 287, 294  
 Botulinum toxin type-A, 215  
 Brain imaging studies, 77, 78  
 Brain stem, involvement in RLS, 76t, 80t  
 Brain structure, studies in RLS, 76t, 77  
 Brain Talk Communities, 322  
 Breast-feeding, RLS treatment/medication considerations, 268-269  
 Bromocriptine, 159t, 185  
 Bupropion, 287, 290t, 293  
  
 Cabergoline, 159t, 185-186  
     half-life, 159t, 185  
     pregnancy risk category, 269t  
     side effects of, augmentation, 177, 185  
 Caffeine, 135, 233, 266  
 CAM (complimentary and alternative medicine), 146-148  
 Carbamazepine, 188t, 198, 293  
     pregnancy risk category, 269t  
 Carbidopa, L-dopa combined with, 173-174, 236  
 Cardiovascular disease  
     as risk factor for RLS, 58  
     RLS impact on, 95-96  
 Catechol-*O*-methyl transferase (COMT) inhibitors, 174-175  
 Central nervous system (CNS). See *Nervous system involvement in RLS*.  
 Cerebellum, involvement in RLS, 76t  
 Cerebrospinal fluid (CSF), 78, 80t  
 Children, RLS in, 16, 65-66, 266-267  
     diagnosis of RLS  
         criteria for, 65, 66t  
         family history and, 47  
         probable or possible RLS diagnosis, 65, 67t  
         diet restrictions, 266  
         nonpharmacologic therapy for, 266  
         pediatricians/specialists, 303t  
         prevalence of RLS, 56, 266  
         sleep hygiene, 266  
         treatment/medication considerations, 266-267  
 Chinese medicine, 147  
 Chiropractic medicine, 147, 148  
  
 Chlordiazepoxide, 211t  
 Chocolate, 266  
 Chronic/persistent/daily RLS, 129t, 130, 239-245  
     defined, 130, 239  
     treatment approaches, 239-245, 240, 241t  
         initial drug therapy, 239-243, 241t  
         nonpharmacologic therapy, 239, 240  
         secondary drug therapy, 243-245  
 Chronicity of RLS, 64-65, 128  
 Cigarette smoking, relationship to RLS, 136, 233  
 Circadian rhythm, 28-29, 77  
     diagnostic questions about, 33t  
     of dopamine, 78-79  
     of RLS symptoms, 28-29, 30, 77  
     sleep hygiene and, 141-142  
 Citalopram, worsening of RLS symptoms with, 292  
 Classification of RLS patients, 128-131, 129t  
     intermittent RLS, 24t, 130, 231  
 Clinical Global Impression (CGI), 112, 112t  
 Clinical picture of RLS, 61-65  
     chronicity of RLS, 64-65  
     clinical significance of symptoms, 24t, 36, 305  
     consensus clinical definition, 15  
     course of RLS, 64-65  
     spectrum of severity, 61-64, 64t  
 Clonazepam, 139, 209, 211t, 212-213, 294  
     dosage, 211t, 212  
     half-life, 212-213  
     pregnancy risk category, 269t  
     use for periodic limb movements (PLMs), 274  
     use for uremic RLS, 265  
     use in children with RLS, 266  
 Clonidine, 215  
     pregnancy risk category, 269t  
     use in children with RLS, 266  
 Clorazepate, 211t  
 Clozapine, onset of RLS linked with, 291  
 Codeine, 202t, 203  
     pregnancy risk category, 269t  
     use for intermittent RLS, 236

- Cognition
- cognitively impaired elderly, 66-69, 68t
  - RLS and, 288-289
  - sleep deprivation effects on, 94
- Cold and cough remedies, 138
- Cold water, 143-144, 146
- Combination treatment, 245, 253-254
- for refractory RLS, 247
- Comorbid conditions, 127-128
- Complete blood count, 116
- Complimentary and alternative medicine (CAM), 146-148
- Compulsive behavior, dopaminergic medications and, 172, 251
- COMT (catechol-*O*-methyl transferase) inhibitors, 174-175
- Concentration, effects of sleep deprivation on, 94
- Confined spaces, exacerbation of RLS by, 26
- Consequences of RLS, 89-104
- avocational impairment, 96-97
  - impact on cardiovascular health, 95-96
  - impact on daytime function, 93-94
    - concentration and cognition, 94
    - fatigue and daytime sleepiness, 93
  - impact on general health, 95
  - impact on mood, 94-95
  - impact on sleep, 89-90, 91, 92
  - impact on travel, 101-102
  - occupational consequences, 99-101
    - disability, 100-101
    - job performance and selection, 99-100
    - relationships with friends and family, 97-99
- Cortex, involvement in RLS, 76t
- Cost of RLS (societal), 16-18
- Counterstimulation techniques, 143-144, 145-146
- Course (progression) of RLS, 64-65, 128
- Cramps, as mimics of RLS, 31, 32t, 35t
- Crisis (RLS crisis or "status"), 64
- Cromolyn, 140t
- Cyberspace RLS Support Group, 322
- CYP1A2 inhibitors, 163
- Daily RLS, 129t, 130, 239-245
- defined, 130, 239
- Daily RLS (*continued*)
- treatment approach, 239-245
    - algorithm for management, 240
    - medications, 239-245, 240, 241t
- Dairy products, 135
- Daytime sleepiness, 93
- benzodiazepines and, 209
- Demerol, pregnancy risk category, 269t
- Demographic factors for RLS, 55t
- Depression, 17, 94-95, 284-287
- co-morbidity with RLS, 58, 94-95, 127, 284-287
    - dopamine agonists for, 241t
  - job-related consequences of, 100
  - major depressive disorder (MDD), 284-287, 285t, 286t
    - medications for, 287
      - worsening of RLS, 95
    - overlapping criteria with RLS, 286, 286t
    - sleep impairment and, 287
    - worsened by RLS medications, 127
- See also *Antidepressants*.
- Desipramine, 290t
- Desloratadine, 140t
- Diabetes
- as causal factor in RLS, 55t, 59
  - laboratory screening for, 116
- Diabetic neuropathy, 31
- Diabetic small-vessel disease, 32t
- Diagnosis of RLS, 21-52, 105-122
- circadian pattern of RLS, 21, 28-29, 30
  - diagnostic criteria, 21-37, 24t-25t
    - in DSM-5, 35-36, 37t, 283
    - IRLSSG (2011) revised criteria, 21-32, 24t-25t, 65
  - diagnostic instruments, 105-107, 107t-109t
    - Epidemiologic Questionnaire, 107t
    - Hopkins Telephone Diagnostic Interview (HTDI), 105-106
    - RLS Diagnostic Index, 106-107
      - Validated Patient-Completed Questionnaire, 108t-109t
  - diagnostic questions, 33t-34t
  - differential diagnosis, 21, 32-34, 33t-35t
    - mimics of RLS, 21, 29-32, 31t-32t
    - periodic limb movement disorder (PLMD), 44, 46t

Diagnosis of RLS, differential diagnosis (*continued*)

- questions to ask, 33, 33t-34t
  - specific issues in, 35t
- DSM-5 and, 34-36, 37t, 95, 283-284, 301
- five diagnostic features (**URGES**), 22-32, 24t-25t
  - Evening or night worse, 25t, 27-29
  - Gets better with (relieved by) movement, 25t, 27
  - questions to elucidate, 33t
  - Rest induced, 25t, 26
  - Solely not accounted by another condition, 25t, 29-32, 31t-32t
  - Urge to move the legs, 22-26, 24t-25t
- initial work-up, 106t
- laboratory evaluation, 106t, 115-118
- misdiagnosis, avoiding, 32-34, 33t-35t
- pain as a descriptor, 25-26
- patient history, 34, 106t
- physical examination, 106t, 115
- quality of life (QOL) evaluation, 113-115, 114
- questionnaires and interviews, 105-107, 107t-109t
- rating scales for RLS, 111-113
  - Augmentation Severity Rating Scale, 112-113, 310-315
  - Clinical Global Impression (CGI), 112, 112t
  - International RLS Study Group Rating Scale, 111
  - Johns Hopkins RLS Severity Scale, 64, 64t
  - Johns Hopkins RLS Syndrome Scale, 111, 111t
  - Patient Global Impression, 112
  - RLS-6 Scales, 112, 113t
- secondary RLS, 69
- sleep diaries, 107-111, 110
- sleep study (polysomnogram), 116-117, 117t-118t
- special populations
  - children, 65-66, 66t, 67t
  - cognitively impaired elderly, 66-69, 68t
  - patients with secondary disorders, 69
- specifiers of (chronic-persistent, intermittent), 24t
- suggested immobilization test (SIT), 28-29, 28t, 117, 119
- supportive diagnostic features, 38-47, 38t
  - family history, 38t, 46-47, 60
  - periodic limb movement disorder (PLMD), 44-45, 46t
  - periodic limb movements in sleep (PLMS) and, 14
  - periodic limb movements (PLM), 38-45, 38t, 39t
  - response to dopaminergic medications, 38t, 45-46

*Diagnostic and Statistical Manual of Mental Disorders*, Fifth

- Edition (DSM-5), 34-36, 37t, 95, 283-284, 301
- Diazepam, 211t
- Dietary/nutritional considerations for RLS, 134-136, 215
  - in children, 266
- Dietary supplements, 215
- Dimenhydrinate, 138
- Diphenhydramine, worsening of RLS with, 137, 209-210, 294
- Disability, qualification for, 100-101
- Dizziness
  - alternative medications for, 140t
  - medications for, 138
  - as side effect of  $\alpha_2\delta$  ligands, 251
  - as side effect of anticonvulsants, 188, 196
  - as side effect of dopaminergics, 251
  - as side effect of opioids, 203
- Dolasetron mesylate, 140t
- Domperidone, 140t
- L-Dopa. See *L-dopa*, under *L*.
- Dopamine
  - circadian rhythm of, 78-79
  - D<sub>1</sub> receptors, 176
  - D<sub>2</sub> receptors, 176, 291
  - iron-dopamine hypothesis for causation of RLS, 78-79, 80t, 81, 82
  - neurotransmission, medication effects on, 78-81, 136-137
  - psychiatric comorbidities of RLS and, 287
- Dopamine agonists, 156t, 157-187, 159t
  - agents (list of specific agents), 159t
  - augmentation with, 176-179, 242, 252
  - cautions
    - for impulse control disorders, 243
    - pregnancy and breast-feeding, 127, 269, 269t
  - in combination therapy, 253-254
  - discontinuing, 182
  - ergot-derived, 159t, 184, 243
  - FDA approved medications for RLS, 158-163, 302
    - pramipexole (Mirapex), 158-163, 159t
    - ropinirole (Requip), 163-164, 164, 165
    - rotigotine (Neupro) transdermal patch, 158, 165-173
  - FDA unapproved, used in treating RLS, 183-187
  - as first-line treatment, 243, 304

- Dopamine agonists (*continued*)
- generic forms of, 242
  - long-acting, 158
  - short-acting (pramipexole, ropinirole), 158
  - side effects, 251
  - tolerance potential of, 250
  - use as pretreatment for surgical procedures, 271
  - use for children with RLS, 266-267
  - use for chronic/daily RLS, 240, 241t, 242
  - use for depressive disorders, 241t, 287
  - use for intermittent RLS, 232, 233t, 237
  - use for refractory RLS, 247, 248
  - use for severe RLS, 241t
  - use for uremic RLS, 263-264
  - use in treatment of PLMD, 274
  - See also *specific agents*.
- Dopaminergic medications, 155-187, 156t
- alternatives to, 140t
  - dopamine agonists, 156t, 157-187, 159t
    - FDA approved for RLS, 158-163, 302
    - FDA unapproved, with applications in treating RLS, 183-187
    - See also *Dopamine agonists*.
  - dopaminergic challenge, 46
  - L-dopa, 155-156, 156t, 173-175
    - See also *L-dopa*.
  - pregnancy risk categories, 269t
  - response to, RLS diagnosis and, 38t, 45-46
  - side effects, 157t, 171-173, 251
    - augmentation and rebound, 173, 173t, 175-183
    - compulsive behaviors, 172
    - intolerable side effects, 251
    - nausea, 171, 251
    - sleep attacks, 172
    - See also *specific medications*.
- DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), 189, 252
- Drug holidays, 247
- Drugs. See *medications*.
- DSM-5 (*Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition), 34-36, 37t, 95, 283-284, 301
- Education and support groups for RLS, 150, 234
- Ekbom, Karl, 11, 15, 200
- Willis-Ekbom Disease (WED), 11-20, 301
- Elderly patients, 269-270
- cognitively impaired, RLS diagnosis in, 66-69, 68t
  - difficulty achieving relief-giving movement, 27
  - drug interaction/multiple drug considerations, 270
  - frequency of PLMS in, 42, 42
  - frequency of RLS in, 269-270
  - pramipexole, dose in, 162
  - serum ferritin screening for, 270
  - treatment concerns, 269-270
- Electromyogram (EMG), 116
- RLS medications as pretreatment for, 271
- End-stage renal disease (ERSD), 263-265
- Endocrinologists, 303t
- Endogenous opiate system, 81, 200
- See also *Opioid medications*.
- Energy therapies, 148
- Entacapone, 175
- Epidemiology of RLS, 53-60
- comorbidity of psychiatric disorders, 58, 127, 284-287, 285t
  - genetic factors, 39-42, 60-61
  - risk factors for RLS, 55-58, 55t
  - secondary RLS, 58-60
- Ergot alkaloid-derived medications, 159t, 184, 243
- Erythropoietin therapy, 263
- Estazolam, 211t
- Eszopiclone, 212t, 214
- pregnancy risk category, 269t
- Ethnicity, RLS and, 53-55, 54
- Evaluation. See *Diagnosis of RLS*.
- Exercise, 144, 234
- lack of, as RLS risk factor, 55t
  - worsening of RLS symptoms by, 181
- Family, effects of RLS on relationships, 97-99
- Family history of RLS, 15, 38t, 46-47, 56-58
- augmentation rates and, 179
  - familial aggregation of RLS, 60-61
- Fatigue, 93

Fatigue Severity Scale, 93  
FDA-approved drugs for RLS, 155, 158-163, 302-304  
  approved dopamine agonists, 158-163, 302  
  non-approved drugs with efficacy for RLS, 155, 183-187  
  transdermal rotigotine patch, 155, 165  
Females, prevalence of RLS in, 54, 55t  
Fentanyl, 202t, 206  
  pregnancy risk category, 269t  
Ferritin  
  serum ferritin level, 234-235, 262  
  high, for prevention of augmentation, 183  
  lab evaluation of, 115-116, 262  
  for children, 266  
  RLS severity and, 234  
  RLS treatment decisions and, 128, 234-235, 262  
Fexofenadine, 140t  
Fibromyalgia, 32t, 59  
Fibrosis, ergot-derived dopamine agonists and, 184, 243  
Fluoxetine, worsening of RLS symptoms with, 292  
Flurazepam, 211t  
fMRI (functional magnetic resonance imaging) studies, 77  
Folic acid, 215, 267-268  
Food and Drug Administration. *See FDA-approved drugs for RLS.*  
Frequency of RLS, 15-16  
Frequency of symptoms, 61, 126-127  
Friends, effects of RLS on relationships, 97-99  
Functional magnetic resonance imaging (fMRI) studies, 77  
Future trends in RLS treatment and research, 302-305  
  
Gabapentin, 188t, 189, 195-197  
  benefit for dialysis patients, 196  
  dosage, 188t, 196  
  in renal impairment, 196  
  efficacy for RLS and PLMS, 195-196, 197  
  extended release (Gralise), 188t, 196-197  
  applications in RLS, 197  
  not FDA approved for RLS, 197  
  FDA approved uses, 196  
  half-life, 196  
  not FDA approved for RLS, 189, 195  
  pregnancy and breast-feeding concerns, 269t

Gabapentin (*continued*)  
  side effects, 196  
  use for chronic/daily RLS, 244  
  use for painful neuropathies, 265  
  use for periodic limb movement disorder (PLMD), 274  
  use for uremic RLS, 264  
Gabapentin enacarbil (Horizant), 157, 188t, 189-195, 304  
  alternatives to, 244  
  bioavailability, 190  
  dosage, 188t, 193  
  in renal impairment, 193  
  efficacy and safety, 190-193, 192-194, 304  
  FDA approved for postherpetic neuralgia, 189  
  FDA approved for RLS, 189, 304  
  as first-line RLS treatment, 243, 304  
  lack of augmentation with, 243  
  not interchangeable with gabapentin, 190  
  as prodrug of gabapentin, 189-190  
  side effects, 193-195  
  tolerability, long-term, 191, 194  
  use for chronic/daily RLS, 240, 243  
  *See also  $\alpha\delta$  ligands; Anticonvulsants.*  
Gastric resection, RLS and, 55t  
Gender  
  depression and, 284  
  RLS and, 54, 55t, 56, 57t  
Genetic factors in RLS, 39-42, 56-58, 60-61  
  familial aggregation of RLS, 60  
  family history of RLS, 46-47, 56-58  
  genes associated with RLS, 39, 61, 62t-63t  
  linkage and association analyses, 39-42, 61, 62t-63t  
  segregation analyses, 60-61  
Gluten, 134-135  
Gralise (gabapentin extended release), 188t, 196-197  
  *See also Gabapentin; Gabapentin enacarbil.*  
Granisetron hydrochloride, 140t  
Gynecologists, 303t

Hallucinations, dopaminergic medications and, 172, 251

HealthBoard.com, 322

Heart

failure, PLMS in, 43t

fibrotic valvular damage, dopamine agonists and, 184, 243

Hematologists, 303t

Herbs, 147

History

family, positive for RLS, 38t, 46-47, 56-58

augmentation and, 179

patient, 34, 106t

Hopkins Telephone Diagnostic Interview (HTDI), 105-106

Horizant. *See Gabapentin enacarbil.*

Hot water and baths, 143-144, 146

Hydrocodone, 202t, 204

pregnancy risk category, 269t

use for intermittent RLS, 236

Hydromorphone, 202t, 206

pregnancy risk category, 269t

Hydroxyzine, worsening RLS with, 138

Hypertension, in RLS patients, 58, 95-96

Hypnotics. *See sedative hypnotics.*

Hypothyroidism, RLS and, 55t

Immobilization test. *See Suggested immobilization test (SIT).*

Impact of RLS. *See Consequences of RLS.*

Impulse control disorders (ICDs)

with dopaminergic medications, 172, 243

with rotigotine, 168-170

screening for, 170

Incidence of RLS, 15-16, 53-55

in children, 266

percentage of general population, 15, 16, 53

Insomnia, 94

treatment with  $\alpha 2\delta$  ligands, 127, 241t

treatment with sedative hypnotics, 209-210, 213-214, 245

Intermittent RLS, 129t, 130, 231-238

defined, 24t, 130, 231

treatment approach, 231-238

algorithm for management, 232

bedtime RLS, frequent, 233t, 236-237

Intermittent RLS, treatment approach (*continued*)

bedtime RLS, infrequent, 233t, 235-236

daytime RLS, expected, 233t, 237

daytime RLS, unexpected, 233t, 238

drug therapy/medications for, 175, 232, 233t, 235-238

all use is off-label, 235

nonpharmacologic therapies, 232-235, 232

one drug fits all needs, 238

International RLS Rating Scale (IRLS), 11, 307-309

IRLS scores, 129, 307-309

International RLS Study Group (IRLSSG)

consensus clinical definition of RLS, 15

diagnostic criteria, 21, 24t-25t, 65

five diagnostic features (**URGES**), 22-32, 24t-25t

Internists, 303t

Intimacy (spousal/bed partner issues), 98-99

Involuntary component of RLS, 12

Ipratropium, 140t

IRLS. *See International RLS Rating Scale (IRLS).*

IRLSSG. *See International RLS Study Group.*

Iron

deficiency

as causal factor in RLS, 15, 58, 69, 79

dopamine and CNS iron, 78-79, 80t, 81, 82

as risk factor for RLS, 55t, 58

secondary RLS due to, 58-59, 261-263

treatment decisions and, 127-128

worsening of RLS symptoms, 181

in refractory RLS, 249-250

delivery system, future, 304-305

ferritin (serum ferritin) as measure of, 234-235, 262

iron-dopamine hypothesis for causation of RLS, 78-79, 80t, 81, 82

status, laboratory evaluation for, 115-116

therapy, 234-235, 261-262

intravenous, 263

iron supplementation, 127-128

oral iron supplementation, 262

in pregnancy, 267

for secondary/uremic RLS, 263



Johns Hopkins Center for RLS, 320  
Johns Hopkins RLS Severity Scale, 64, 64t  
Johns Hopkins RLS Syndrome Scale (JHRLSS), 111, 111t

#### Kidney transplantation

improvement of RLS after, 263  
secondary RLS after, 149

#### L-dopa, 46, 155-156, 156t, 173-175

augmentation due to daily use, 156, 176-179  
intermittent use to avoid, 156, 175, 177  
treatment of, 181-182  
dosage, 174, 179  
extending with COMT inhibitors, 174-175  
formulations, 173-174  
combined with carbidopa or benserazide, 173-174  
immediate-release, 174  
half-life, 174, 175  
intermittent use to avoid augmentation, 156, 175, 177  
pregnancy risk category, 269t  
side effects of, 156, 157t, 174  
augmentation, 156, 176-179  
rebound, 175-176  
use as “one drug fits all needs,” 238  
use as pretreatment for outpatient procedures, 271  
use for children with RLS, 266  
use for intermittent RLS, 175, 232, 233t, 236, 237, 238  
use for periodic limb movement disorder (PLMD), 274  
use for uremic RLS, 264

#### Laboratory evaluation for RLS, 106t, 115-118

Lamotrigine, 188t, 199, 293

Laudanum, used for RLS, 14

#### Legs

counterstimulation techniques, 145-146  
leg cramps, 25-26, 31, 32t, 35t  
leg discomfort, disorders of, 31, 32t  
leg shaking, 35t  
leg symptoms with toe dyskinesias, 31t

Levetiracetam, 188t, 199

Levodopa. See *L-dopa*.

Levorphanol, 202t, 206

pregnancy risk category, 269t

#### Lifestyle factors in RLS

lifestyle disruptions, 93-94  
sleep disruption, 89-90

Lifestyle modifications. See *nonpharmacologic management of RLS*.

Lisuride, 159t, 184, 186

Lithium, 293-294

exacerbation of RLS/PLMS reported for, 43t, 293, 293-294

Loratadine, 140t

Lorazepam, 211t

worsening of RLS with, 139, 209-210

Lyrica. See *Pregabalin*.

Machado-Joseph disease, RLS and, 55t

#### Magnesium

deficiency, RLS and, 55t

as RLS therapy, 215

Major depressive disorder (MDD), 284-287, 285t, 286t

Management of RLS, 123-230

classification of RLS patients, 128-131, 129t

daily RLS, 129t, 130

intermittent RLS, 129t, 130

refractory RLS, 129t, 130

comorbid conditions, 127-128

dietary and nutritional considerations, 134-136

follow-up and adjustment, 128

future trends in, 302-305

general guide to, 124t

iron deficiency and, 127-128

lifestyle modifications, 133-153

medications. See *Medications*.

nonpharmacologic management, 133-153, 134t

See also *Nonpharmacologic management of RLS*.

patient approach

chronic-persistent/daily RLS, 239-245, 240

combination treatment, 245, 253-254

drug holidays, 247

individualized treatment, 253-256

intermittent RLS, 231-238, 232, 233t

referrals, 246, 256-257

refractory RLS, 245-252, 247

rotating treatment, 255-256

Management of RLS (*continued*)

- preventive treatment, 125
- special populations. See *Special populations*.
- tailoring treatment to symptoms, 123-128
  - adjustment of treatment, 124t, 128
  - following the patient, 128
  - frequency and severity of symptoms, 126-127
  - timing of doses, 124t
  - timing of symptoms, 124t, 125-126
  - when to treat, 123-125, 124t

See also *Medications; Treatment of RLS*.

Mania, 31t

Manipulative methods, 147

Massage, as relief-giving activity, 23, 144, 146, 147

MDD. See *major depressive disorder (MDD)*.

Meclizine, reports of worsening RLS with, 138

Medical-alert card for RLS, 233

Medications, 155-230

- anticonvulsants, 156t, 188-200, 188t
  - $\alpha 2\delta$  ligands, 156t, 189-195
  - gabapentin, 156t, 195-197
    - not FDA-approved for RLS, 189, 195
  - gabapentin enacarbil (Horizant), 189-195
    - FDA-approved for RLS, 189, 304
  - other anticonvulsants, 198-200
  - pregabalin (Lyrica), 156t, 197-198
- for children with RLS, 266-267
- choosing
  - initial drug therapy, 239-243, 241t
  - secondary drug therapy, 243-245
- classes of drugs, 155, 156t
  - anticonvulsants, 156t, 188-200, 188t
  - dopaminergics, 155-156, 156t
  - opioids, 156t, 200-208, 202t
  - other pharmacologic options, 215
  - sedative hypnotics, 156t, 209-215, 211t
- dopaminergics, 155-187, 156t
  - augmentation and rebound, 173, 173t, 175-183
  - dopamine agonists, 157-187, 159t
    - pramipexole, 158-163, 159t
    - ropinirole, 163-164
    - rotigotine, 165-173

Medications, dopaminergics (*continued*)

- L-dopa, 155-156, 173-175
  - side effects, 157t, 171-173, 173t
  - FDA-approved for RLS, 155, 158-163, 302-304
  - for moderate to severe RLS, 129, 161, 163, 165
  - FDA-unapproved for RLS, but with effect applications, 155, 183-187, 195-198
  - follow-up and flexibility in, 128
  - future trends and prospects, 302-305
  - multiple doses, 126
  - opioids, 156t, 200-208, 202t
    - side effects of, 203
  - for other conditions, considerations for RLS, 136-139, 140t
  - patient approaches
    - chronic/persistent/daily RLS, 239-245, 240, 241t
    - combination treatment, 245, 253-254
    - drug holidays, 247, 255
    - individualized treatment, 253-256
    - initial drug therapy, choice of, 239-243, 241t
    - intermittent RLS, 231-238, 232, 233t
    - “one drug fits all needs,” 238
    - refractory RLS, 245-252, 247
    - rotating treatment, 255-256
  - pregnancy and breast-feeding, 267-269, 269t
  - prophylactic use of, 125
  - psychiatric, 136-137, 289-294
    - worsening of RLS symptoms, 138, 181, 289-293
  - RLS-friendly, 139, 140t, 215, 290t
  - RLS-friendly and unfriendly effects of, 127, 136-139, 181
  - sedative hypnotics, 156t, 209-215, 211t
    - benzodiazepines, 210-213, 211t
    - nonbenzodiazepines, 212t, 213-215
  - side effects. See *specific medications*.
  - timing of doses, 124t, 125-126
  - worsening of RLS symptoms with, 138-139, 181, 209-210, 289-293
    - avoiding, 232-233
- See also *specific medications and drug classes*.
- Melanoma risk, dopaminergic medications and, 171
  - Melatonin, RLS and, 29, 77
  - Mental alerting activities, 145

Mental disorders, 31t, 283-299  
 RLS association with, 58, 283-299  
 See also *DSM-5*.

Meperidine, 202t

Methadone, 202t, 206-208, 304  
 half-life, 208  
 pregnancy risk category, 269t  
 use for refractory RLS, 247, 248-249  
 use for treatment of RLS augmentation, 183  
 use in pregnant and breast-feeding women, 268, 269

Metoclopramide, worsening of RLS with, 138, 289

Mimics of RLS, 29-32, 31t-32t  
 leg discomfort disorders, 31, 32t  
 questions to differentiate RLS from, 33t-34t  
 restlessness disorders, 29-31, 31t

Mind-body interventions, 147

Minerals, 215

Mirapex. See *Pramipexole*.

Mirtazapine, 293

Moderate-to-severe RLS, 129  
 FDA-approved medications for, 129, 161, 163, 165

Montelukast, 140t

Mood  
 effect of RLS on, 94-95  
 See also *Anxiety; Depression; Psychiatric disorders*.

Morphine, 202t, 208  
 pregnancy risk category, 269t

Movements  
 involuntary component, 12  
 movement disorders, 31t  
 relief of symptoms with, 12, 27  
 questions to elucidate diagnosis, 33t-34t  
 repetitive, 12  
 urge to move, 22-26, 24t, 25t  
 voluntary component, 12  
 See also *Periodic limb movements (PLM)*.

Movies  
 medication use and, 237  
 RLS effects and, 97

MRI scans, 77

Multiple sclerosis, RLS and, 55t

Muscle cramps, 25-26, 31, 32t, 35t

Naloxone, 81

Narcolepsy, PLMS in, 42, 43t

National Heart, Lung, and Blood Institute (NHLBI), 320

National Institute of Neurological Disorders and Stroke (NINDS), 320

National Institutes of Health (NIH), 320

National Sleep Foundation, 322

Nausea  
 medications for, 138, 140t  
 as side effect of dopaminergic medications, 171, 251  
 as side effect of opioids, 203

Nefazodone, 290t

Nerve disorders, as RLS mimics, 32t, 35t

Nervous system involvement in RLS, 75-88  
 nervous system dysfunction, 75-78, 76t  
 circadian rhythms, 77  
 CNS dysfunction, 75-78  
 electrophysiologic studies, 75  
 imaging studies, 77  
 neurotransmitter systems, 78-79  
 dopamine and CNS iron, 78-79, 80t, 81, 82  
 other systems/endogenous opiate system, 81-83

Neupro. See *Rotigotine*.

Neuroleptic medications, 136-137, 289-291  
 alternatives for, 290t

Neurologic exam, 115

Neurologists, 302, 303t

Neuropathies  
 anticonvulsants for, 189, 197  
 as causal factors in RLS, 59  
 painful  
 comorbid with RLS, 127, 265  
 treatment of, 265  
 as RLS mimics, 32t  
 See also *Posttherapeutic neuralgia*.

Neurotransmitter systems, 78-81

Nicotine/cigarette smoking, 136  
 abstinence from, 233

“Night walkers” (symptom), 89, 90

*NightWalkers* (newsletter), 150

Night worse (diagnostic feature), 25t, 27-29

- Nonbenzodiazepines, 212t, 213-215, 274
- Nonpharmacologic management of RLS, 133-153, 134t
- alternative treatments, 146-148
    - alternative medical systems, 147
    - complimentary and alternative medicine (CAM), 146-148
  - avoidance of provocative substances, 134-139, 134t
  - “bag of tricks,” 233-234
  - for children, 266
  - considerations for medications, 136-139, 140t
    - antihistamines, 137-138
    - antiemetic, and antidizzy medications, 138
    - RLS-friendly alternative drugs, 139, 140t, 215, 290t
  - counterstimulation techniques, 145-146
  - dietary and nutritional considerations, 134-136, 233
    - alcohol, 135-136, 233
    - caffeine, 135, 233
    - iron supplementation, 127-128, 234-235
    - tobacco, 136, 233
  - exercise, 144, 234
  - medications, considerations for, 136-139, 140t
  - mental alerting activities, 145
  - patient approach
    - chronic/persistent/daily RLS, 239, 240
    - intermittent RLS, 232-235, 232
  - patient organizations and support, 150
  - patient preference for, 133
  - sleep hygiene, 139-144, 234
  - surgery, 148-149
  - use for uremic RLS, 263
  - See also *Medications*.
- Nutritional considerations for RLS, 134-136, 215
- Obesity
- medication decisions and, 127
  - RLS and, 55t, 58
- Obsessive-compulsive disorder, 31t
- Obstetricians, 303t
- Obstructive sleep apnea, PLMS in, 43t
- Oncologists, 303t
- Ondansetron hydrochloride, 140t
- Opioid medications, 81, 156t, 200-208, 202t, 304
- action mechanism, 200
  - agents, specific, 202t
  - cautions for prescribing, 205, 245, 249
  - combined with acetaminophen, aspirin, or ibuprofen, 201
  - efficacy for RLS, 200-201, 304
  - endogenous opiate system and, 81, 200
  - formulations of, 201, 202t
  - high-potency, 202t, 205-208
    - fentanyl transdermal patches, 202t, 206
    - hydromorphone, levorphanol, and oxycodone, 202t, 206
    - methadone, 202t, 206-208
    - morphine, 202t, 208
    - oxycodone, 202t, 208
    - use for refractory RLS, 206-207, 247, 248-249
    - use for RLS augmentation, 181, 183, 205
  - historical use of, 14
  - low-potency, 202t, 203-204
    - codeine, 202t, 203
    - propoxyphene, 202t, 204
    - use for chronic/daily RLS, 240, 244
    - use for intermittent RLS, 232, 236, 237, 238
  - medium-potency, 202t, 204-205
    - hydrocodone, 202t, 204
    - tramadol, 202t, 204-205
    - use for chronic/daily RLS, 240, 244
    - use for intermittent RLS, 236, 237, 238
  - pregnancy and breast-feeding concerns, 269, 269t
  - respiratory depression with, 203, 245
  - reversal of therapeutic effect with naloxone, 81
  - side effects of, 203
  - tolerance
    - cross-tolerance among opioids, 256
    - and dependence potential, 201, 205
  - use as “one drug fits all needs,” 238
  - use for chronic/daily RLS, 240, 244-245
  - use for intermittent RLS, 232, 233t, 236, 237, 238
  - use for PLMD, 274
  - use for quick onset/action, 254, 271-272
  - use for refractory RLS, 200
  - use for RLS in pregnancy, 268

## Opioid medications (*continued*)

- use for surgery, PLM control and RLS symptoms, 271-272
  - use for treatment of augmentation, 181, 183, 252
  - use for uremic RLS, 264-265
- Osteoarthritis, as RLS mimic, 32t
- Osteopathic manipulation, 147
- Oxazepam, 211t
- Oxcarbazepine, 188t, 199
- Oxycodone, 202t, 208
- pregnancy risk category, 269t
  - use for refractory RLS, 247
  - use for treatment of RLS augmentation, 183
  - use in pregnant women, 268
- Oxymorphone, 202t, 206

## Pain

- chronic, fentanyl patches for, 206
  - comorbid with RLS, worsened by medications, 127
  - as component of RLS symptoms, 25
  - pain syndromes, as RLS mimics, 31, 32t, 35t
  - painful RLS symptoms
    - $\alpha\delta$  ligands for, 241t
    - anticonvulsants for, 189
  - RLS symptoms differentiated from, 25-26
- Pallidotomy, 149
- Panic disorder, 284-285, 285t, 286-287
- Parkinson's disease (PD)
- COMT inhibitors for, 175
  - drugs used in treatment of, 265
  - side effects, 157t
  - See also *Dopaminergic medications*.
  - PLMS in, 43t
  - relationship to RLS, 55t, 60, 265
- Paroxetine, worsening of RLS symptoms with, 292
- Pathophysiology of RLS, 75-88
- dopamine and CNS iron, 78-79, 80t, 81, 82
  - nervous system dysfunction, 75-78, 76t
  - neurotransmitter systems, 78-81
  - other systems/endogenous opiate system, 81-83
- Patient approach, 231-259
- chronic-persistent/daily RLS, 239-245, 240
  - drug holidays, 255

## Patient approach (*continued*)

- individualized treatment, 253-256
  - intermittent symptoms, 231-238, 232
  - refractory RLS, 245-252, 247
  - rotating treatment, 255-256
- See also *Management of RLS; specific categories of RLS*.
- Patient Global Impression, 112
- Patient history, 34, 106t
- Patient organizations, support groups, and resources, 150, 321-323
- PCP. See *primary care physician (PCP)*.
- PD. See *Parkinson's disease*.
- Pediatric RLS, family history in diagnosis of, 47
- Pediatricians, 303t
- Pentazocine, 202t
- Pergolide, 159t, 186
- dosage, 159t
  - fibrosis linked to, 184
  - pregnancy risk category, 269t
  - side effects of, 186
    - augmentation, 177
  - use for periodic limb movement disorder (PLMD), 274
  - use in uremic RLS, 264
  - withdrawn from US market, 186, 268
- Periodic limb movements (PLM), 12-14, 38-45, 40-41
- actigraphic measurement of, 44, 118
  - age and, 42, 42
  - association with RLS, 38-39, 43-44
  - categories of patients with, 272-274
  - criteria for, 13t, 39t
  - defined, 13t
  - diagnosis of, 39t
  - in diagnosis of RLS, 14, 38-45, 39t, 40-41
    - diagnostic utility of, 43-44
  - electromyogram (EMG) measurement of, 28t
  - epidemiology of, 39-42, 42
  - management of patients with, 272-274
  - measurement/detection of, 40-41, 44
  - medications for, 274
    - during surgery/outpatient procedures, 270-271
  - pramipexole, 274
  - pregabalin, 197
  - questions/debate over whether to treat, 272

Periodic limb movements (PLM) (*continued*)  
   nonpharmacologic measures, 272-273  
   polysomnographic measurement of, 116-117, 117t, 118t  
   spousal/bed partner issues, 98-99, 272-273  
   in surgery/outpatient procedures, 270-271  
   treatment considerations, 272-274

Periodic limb movement arousal index (PLMAI), 13t

Periodic limb movement disorder (PLMD), 13t, 44-45  
   defined, 13t  
   diagnostic criteria, 45t  
   differences from RLS, 44, 46t  
   treatment considerations, 46t

Periodic limb movement index (PLMI), 13t, 45t

Periodic limb movements in sleep (PLMS), 12-14, 13t, 38-39  
   in ADHD, 287-288  
   conditions associated with, 43t  
   defined, 13t  
   effectiveness of gabapentin for, 274  
   polysomnogram measurement of, 45t, 116-117, 117t, 118t  
   psychiatric medications, effect on, 291-292  
   sleep stages and, 38-39

Periodic limb movements in wake (PLMW), 13t, 39  
   defined, 13t  
   fMRI of brain activity during, 77

Peripheral nervous system, 76t, 78

PET (positron emission tomography), 77, 78

Pharmacologic management. *See medications.*

Physical examination, 106t, 115

Pimozide, onset of RLS linked with, 291

Piribedil, 159t, 186

Placebo effect, 209

PLM. *See periodic limb movements (PLM).*

PLMD. *See periodic limb movement disorder (PLMD).*

PLMS. *See periodic limb movements in sleep (PLMS).*

PLMW. *See periodic limb movements in wake (PLMW).*

Polyneuropathies, 32t, 55t

Polysomnogram (PSG), 116-117, 117t  
   typical findings, 118t  
   utility in RLS diagnosis, 45t

Positron emission tomography (PET), 77, 78

Postherpetic neuralgia  
   gabapentin enacarbil approved for, 189  
   gabapentin extended release (Gralise) approved for, 196  
   pregabalin approved for, 197

Pramipexole (Mirapex), 158-163, 159t  
   approval for RLS, 161  
   dosage, 158-162, 159t, 162  
     cautions on more than once a day dosing, 162-163  
   drugs that reduce elimination of, 161  
   efficacy and safety, 158-161, 160, 162  
   in elderly patients, 162  
   half-life, 159t, 161  
   onset of effective action, 161  
   pramipexole ER, 187, 243-244  
   pregnancy risk category, 269t  
   side effects, 157t, 171-173  
     augmentation, 177, 302  
   use for children with RLS, 267  
   use for chronic/daily RLS, 240, 242, 243-244  
   use for periodic limb movement disorder (PLMD), 274  
   use for uremic RLS, 264

Pregabalin (Lyrica), 156t, 188t, 189, 197-198  
   applications in RLS, 197-198  
   dosage, 188t, 244  
   FDA approved uses, 197  
   half-life, 197-198, 244  
   not FDA approved for RLS, 197  
   side effects, 198  
   use for chronic/daily RLS, 240, 244  
   use for painful neuropathies, 265  
   use for secondary RLS, 265

Pregnancy, 56, 267-268  
   Category C drugs, to be avoided during, 127, 268, 269t  
   as causal factor in RLS, 15  
   drug risk categories, 268, 269t  
   drugs to avoid, 127, 268, 269t  
   iron therapy, 267  
   PLMS in, 43t  
   as risk factor for RLS, 55t, 56, 59  
   RLS treatment considerations, 241t, 267-269  
   safer medications for, 268, 269t

- Prevalence of RLS, 53-55, 266
- Primary care physician (PCP), 256
  - prescription of opioids, 256
  - referrals to specialists, 246, 247, 256-257, 302, 303t
  - treatment of RLS, 256
- Prochlorperazine, worsening of RLS with, 138, 289
- Progression of RLS, 64-65, 128
- Promethazine, worsening of RLS with, 138, 289
- Prophylactic use of medications, 125
- Propoxyphene, 202t, 204
  - pregnancy risk category, 269t
  - withdrawn from US market, 204
- Propranolol, 215
- PSG. *See polysomnogram (PSG).*
- Psychiatric disorders, RLS and, 31t, 283-299
  - ADHD, 287-288
  - cognition, 288-289
  - depression and anxiety, 58, 127, 283, 284-287, 285t
  - DSM-5 and, 34-36, 37t, 95, 283-284, 301
  - epidemiology and mechanisms, 287
  - major depressive disorder (MDD), 284-287, 285t
  - overlapping and distinctive criteria, 286, 286t
  - panic disorder, 284-285, 285t, 286-287
  - psychiatric medications, 136-137, 289-294
    - antidepressants, 291-293
    - lithium, 293-294
    - neuroleptic medications, 289-291
    - RLS-compatible medications, 290t
    - side effects of, 289
    - worsening of RLS symptoms, 138, 181, 289-293
  - See also Anxiety; Depression*
- Psychiatrists, 301
- Quality of life (QOL) in RLS, 95, 96-97, 113-115, 114
  - RLS-QOL instrument, 115
  - Short Form 36 Health Survey scores, 93, 95, 114
- Quazepam, 211t
- Questionnaires and interviews, 105-107, 107t-109t
  - sleep questionnaires, 93-94, 95
- Radiculopathies, as RLS mimics, 32t
- Ramelteon, 212t, 214
- Rash, skin, 189
- Rating scales for RLS, 111-113, 111t, 112t
  - Augmentation Severity Rating Scale, 112-113, 310-315
  - IRLS rating scale, 11, 307-309
  - quality of life scales, 93, 95, 114
- Rebound, 175-176
  - augmentation confused with, 181
- Reboxetine, 290t
- Referrals for RLS patients, 246, 256-257, 302
- Refractory RLS, 129t, 130, 245-252
  - defined, 130, 245
  - treatment approach, 245-252, 247
    - algorithm for management, 247
    - augmentation, uncontrollable, 247, 252
    - combination therapy, 247
    - drug holidays and rotating drugs, 253
    - inadequate initial response, 246-249, 247
    - intolerable side effects, 251-252
    - medications, 245-252, 247
    - opioids for, 202, 206-207, 247
    - referral to specialists, 246, 247, 256-257
    - response becomes inadequate despite increasing doses, 247, 249-250
    - worsening due to a new trigger, 249
    - worsening due to decreased iron, 249-250
    - worsening due to disease progression, 250
    - worsening due to tolerance, 250
  - See also Severe RLS.*
- REM sleep, 38-39
- REM sleep behavior disorder, 42, 43t
- Renal failure
  - as causal factor in RLS, 58
  - end-stage renal disease (ERSD), 149
  - gabapentin, benefit for dialysis patients, 196
  - kidney transplantation, 149
  - as risk factor for RLS, 55t, 58, 59
  - uremia and secondary RLS in, 149, 263-265
- Renal impairment
  - gabapentin dosage in, 196
  - gabapentin enacarbil dosage in, 193
  - medication choices and, 241t

- Renal specialists, 303t
- Repetitive movement habits, 31t
- Repetitive movements, 12
- Requip. See *Ropinirole*.
- Resources on RLS, 317-323
  - books, 317-319
  - patient organizations and resources, 321-323
  - web sites and resources, 319-323
- Rest induced (diagnostic feature), 25t, 26
  - questions to elucidate, 33t
- REST (RLS Epidemiology, Symptoms and Treatment) studies, 15, 89-90
  - elderly RLS patients, prevalence of, 269-270
  - gender in, 54
  - severity of RLS, 61
  - sleep, effects of RLS on, 89-90, 91, 92
- Restless Legs Syndrome (RLS)
  - about, 11-20
  - chronicity and progression of, 64-65, 128
  - classification of patients, 128-131, 129t
  - classifications of, intermittent RLS, 24t, 130, 231
  - clinical significance of symptoms, 24t, 36, 305
  - commonness/incidence of, 15-16, 53-55
  - consensus clinical definition of, 15
  - consequences of. See *Consequences of RLS*.
  - diagnosis of. See *Diagnosis of RLS*.
  - education/support groups for, 150, 234
  - historical descriptions of, 14-15
  - impact on patients, 89-104
  - management of. See *Management of RLS*.
  - medical-alert card for, 233
  - mimics of, 29-32, 31t-32t
  - morbidity and cost of, 16-18
  - patient description of symptoms, 11-12, 12t, 18, 22-23
  - resources on, 317-323
  - secondary RLS, 16, 58-60, 261-265
  - as sensorimotor disorder, 11-14
  - severe cases. See *Severe RLS*.
  - treatment of. See *Treatment of RLS*.
  - trends and future prospects in, 302-305
  - WED (Willis-Ekbom Disease) as interchangeable name for, 11, 301
- Restless Legs Syndrome (RLS) Foundation. See *RLS Foundation*.
- Restlessness, disorders of, 29-32, 31t
- Rheumatoid arthritis, 32, 32t, 59
- Rheumatologists, 303t
- RiBECA study, 285-286
- Risk factors for RLS, 55-58, 55t
  - age, 55t, 56
  - cardiovascular, 95
  - family history of RLS, 56-58, 60-61
  - reducing, 305
  - sex (gender), 54, 56, 57t
- RLS-6 Scales, 112, 113t
- RLS Diagnostic Index (RLS-DI), 106-107
- RLS Foundation, 150, 234, 321-322
  - finding specialists through, 302
  - pamphlets and videos, 321-322
- RLS in Baltimore Epidemiologic Catchment Area (RiBECA) study, 285-286
- RLS-PLMD at Yahoo Groups, 322
- The RLS Rebel Web site, 323
- Ropinirole (Requip), 159t, 163-164
  - approval for RLS, 163
  - dosage, 159t, 163-164
  - drugs that slow metabolism of, 163
  - efficacy, 163, 164, 165
  - half-life, 159t, 163, 242
  - onset of effective action, 163-164
  - pregnancy risk category, 269t
  - ropinirole (Requip) XL, 187, 244
  - side effects, 157t, 171-173
  - use for children with RLS, 266-267
  - use for chronic/daily RLS, 240, 242, 244
  - use for periodic limb movement disorder (PLMD), 274
  - use for uremic RLS, 264
- Rotating treatment, 255-256
- Rotigotine (Neupro), 159t, 165-173
  - dosage, 166-167, 167, 170
  - efficacy, 166-167, 167, 169t
  - FDA approval of, 155, 165
  - as first-line treatment, 243, 304
  - half-life, 159t



## Rotigotine (Neupro) (*continued*)

- pregnancy risk category, 269t
- reformulation and reapproval of, 165
- safety and tolerability, 165, 166, 170
- side effects, 157t, 171-173
  - application site reactions, 251
  - augmentation (fewer problems with), 170, 177-179, 302-304
  - impulse control disorders (ICDs), 168-170, 172
- as transdermal patch, 155, 165, 166
  - application of, 170
- use for chronic/daily RLS, 240

## Scleroderma, 59

### Sclerotherapy, 148

### Scopolamine patches, 140t

## Secondary RLS, 16, 58-60, 261-265

- defined, 261
- diagnosis of, 69
- iron deficiency and anemia, 58-59, 69, 261-263
- neurologic and endocrine disorders, 265
- other secondary RLS conditions, 265
- pregnancy and, 56
- treatment considerations, 261-265
  - treating the underlying disorder, 265
- uremia/uremic RLS, 263-265

## Sedation

- as an advantage at bedtime, 188, 193
- as  $\alpha\delta$  ligand side effect, 251
- as anticonvulsant side effect, 188, 193
- as opioid side effect, 203

## Sedative hypnotics, 138-139, 156t, 209-215, 211t, 254

- benzodiazepines, 210-213, 211t
  - alprazolam, 210-212, 211t
  - clonazepam, 209, 211t, 212-213
  - placebo effect and, 209
  - temazepam, 211t, 213
  - triazolam, 211t, 213
  - use for uremic RLS, 265
- FDA approved for treatment of insomnia, 209
- improvement of RLS symptoms with, 209

## Sedative hypnotics (*continued*)

- nonbenzodiazepines, 212t, 213-215
  - eszopiclone and zaleplon, 212t, 214
  - ramelteon, 212t, 214
  - zolpidem, 212t, 214-215
- pregnancy risk categories, 269t
- side effects, risks for daytime functions, 209
- tolerance potential of, 210, 213, 214
- use for chronic/daily RLS, 240
- use for insomnia and sleep disruption, 209-210, 245
- use for intermittent RLS, 233t, 236
- worsening of RLS symptoms with, 138-139, 209-210
- See also *specific medications*.

## Selective serotonin reuptake inhibitors (SSRIs)

- improvement of RLS symptoms with, 292
- increase in PLMs/PLMS with, 43t, 135
- worsening of RLS symptoms with, 137, 291-292

## Sensorimotor components of RLS, 11-14

## Sensory symptoms, 11-14

## Serotonin-norepinephrine reuptake inhibitors (SNRIs), 291-292

## Sertraline, worsening of RLS symptoms with, 292

## Severe RLS

- disability as result of, 100-101
- frequency of symptoms, 61, 126
- Johns Hopkins RLS Severity Scale, 64, 64t
- opioids for, 200, 206-207
- pain in, 25
- quality of life and, 113-115, 114
- RLS crisis or "status," 64
- specialists for, 131
- spectrum of severity, 61-64
- use of dopamine agonists for, 241t
- See also *Refractory RLS*.

## Severity of RLS

- classification of patients, 128-131, 129t
- spectrum of severity, 61-64, 64t
- treatment decisions and, 129-131

## Sex, as risk factor for RLS, 54, 55t, 56, 57t

## Shift work, 100, 141-142

## Short Form 36 Health Survey (SF-36), 93, 95, 114

## Single-photon emission computed tomography (SPECT), 77, 78

SIT. See *suggested immobilization test (SIT)*.

Sjogren's syndrome, 59

Skin rash, 189

## Sleep

alcohol and, 135-136

counterstimulation techniques and, 143-144

deprivation, 17, 93, 181

sleep hygiene for, 139-141, 234

diaries (sleep diaries), 107-111, 110

disruption, 17, 209

evaluation

polysomnogram, 116-117, 117t

sleep diaries, 107-111, 110

exercise and, 144

hygiene, 139-144, 234

avoiding sleep deprivation, 139-141

bedroom, preparation of, 142-143

for children, 266

counterstimulation practices, 143-144

pre-sleep activity, 143-144

regular bedtimes and rise times, 141-142

impact of RLS on, 89-90

daytime sleepiness, 93

difficulty getting to sleep, 89-90, 91

difficulty maintaining sleep, 90, 92

insomnia, 94

medications for, 209-210, 213-214, 245

medications

$\alpha\delta$  ligands, 241t

dopamine agonists and, 251

gabapentin, 194-195

gabapentin enacarbil, 191-193

OTC sleeping pills, 138

placebo effect and, 209

pramipexole, 161, 162

pregabalin, 197

ropinirole, 163, 165

sedative hypnotics, 138-139, 156t, 209-215, 211t, 254

narcolepsy

PLMS in, 42, 43t

sudden sleep attacks with dopaminergic medications, 172

## Sleep (continued)

National Sleep Foundation, 322

"night walkers" (symptom), 89, 90

NREM sleep, 38

REM sleep, 38-39

REM sleep behavior disorder, 42, 43t

scales, questionnaires, surveys, and studies, 93-94, 95, 111

sleep states, 191

polysomnographic measurement of, 117t, 118t

sleep study (polysomnogram), 116-117, 117t, 273

specialists, referrals to, 302

See also *Periodic limb movements in sleep (PLMS)*.

Sleep apnea

medications and, 127

PLMS in, 43t

Smoking, relationship to RLS, 136, 233

Snoring, 44

SNRIs. See *serotonin-norepinephrine reuptake inhibitors (SNRIs)*.

Social events, RLS and, 96-97

Socioeconomic status, as RLS risk factor, 55t

Sodium oxybate, onset of RLS linked to, 139

Sodium tetradecyl sulphate, 148

The Southern California RLS Support Group, 323

Special populations, 65-69, 261-281

children, 65-66, 66t, 266-267

elderly, 269-270

cognitively impaired elderly, 66-69, 68t

periodic limb movement disorder (PLMD), 272-274

pregnant and breast-feeding women, 267-269

secondary RLS, 261-265

iron deficiency with or without anemia, 261-263

other secondary RLS conditions, 265

uremia, 263-265

surgery or outpatient procedures, 270-272

Specialists, 303t

referrals to, 246, 247, 256-257, 302, 303t

SPECT (single-photon emission computed tomography), 77, 78

Spinal cord, involvement in RLS, 76t

Spinocerebellar ataxia type 3, RLS and, 55t

SSRIs. See *selective serotonin reuptake inhibitors (SSRIs)*.

Steroid, as RLS-friendly drug, 140t

- Suggested immobilization test (SIT), 28, 28t, 117, 119
- Suicide and ideation, 188, 252
- Support groups, 150, 234
- Suprachiasmatic nucleus, circadian rhythms and, 77
- Surgeons, 303t
- Surgery, 148-149, 270-272
  - improvement of RLS after, 148-149
  - outpatient procedures, 271-272
  - PLMs during, 270-271
  - RLS treatment concerns, 270-272
  - worsening of RLS after, 149, 271
- Symptoms, 11-14
  - circadian pattern of, 28-29, 30, 77
  - clinical significance of, 24t, 36
  - confined spaces and, 26
  - differentiated from pain, 25-26
  - frequency of, 61, 126-127
  - patient classification by, 129t
  - patient description of, 11-12, 12t, 18, 22-23
  - persistence of, RLS diagnosis and, 23
  - psychiatric disorders, symptomatic overlap with RLS, 286, 286t
  - relief by movement, 12
  - sensations associated with, 11-12, 12t
  - specifiers of (chronic-persistent, intermittent), 24t
  - treatment decisions and, 123-128
    - follow-up, 128
    - frequency and severity of symptoms, 126-127, 235-239
    - timing of symptoms, 124t, 125-126, 241t
    - when to treat, 123-125, 124t
  - urge to move legs and other body parts, 11-12, 22-26
  - worsening of
    - augmentation, treatment of, 181-183
    - medications and, 138-139, 181, 209-210, 289-293
    - night worse (diagnostic feature), 25t, 27-29
    - surgery and, 149

See also *Diagnosis of RLS; Periodic limb movements (PLM)*.

Talk About Sleep, 323

Teenagers, RLS in, 16, 266

Temazepam, 211t, 213
  - contraindicated in pregnancy, 269t
  - use for periodic limb movements (PLMs), 274

Terguride, 87, 159t

Thalamus, involvement in RLS, 76t

Theater and movies, RLS effects and, 97

Tiagabine, 188t, 189

Tic disorder, 31t

Tobacco/smoking, 136, 233

Toes, movements/dyskinesias, 31t, 35t

Tolcapone, 175

Tolerance
  - augmentation, similarities to, 181
  - cross-tolerance, 256
  - drug holidays as means of avoiding, 255
  - opioids and, 201, 205
  - rotating treatment as means of avoiding, 255-256
  - to sedative hypnotics, 210, 213, 214
  - worsening of RLS due to, 250

Topiramate, 188t, 199

Tramadol, 202t, 204-205
  - action mechanism, 204-205
  - augmentation with, 176
  - efficacy in RLS, 205
  - extended-release, 202t
  - pregnancy risk category/concerns, 269, 269t
  - use for intermittent RLS, 236, 237, 238

Transdermal patch. See *Rotigotine*.

Travel
  - impact of RLS on, 101-102
  - mental alerting activities for, 145

Trazodone, 290t, 293

Treatment of RLS, 123-230
  - adjustment of, 124t
  - algorithms for
    - daily RLS, 240
    - intermittent RLS, 232
    - refractory RLS, 247
  - alternative treatments, 146-148
  - classification of RLS patients, 128-131, 129t
  - follow-up and adjustment, 128
  - future trends for, 302-305
  - general guide to treatment decisions, 124t
  - nonpharmacologic management. See *Nonpharmacologic management of RLS*.

## Treatment of RLS (*continued*)

- patient approach, 231-259
  - chronic/persistent/daily RLS, 239-245, 240, 241t
  - combination treatment, 245, 247, 253-254
  - drug holidays, 247, 255
  - individualized treatment, 253-256
  - intermittent RLS, 231-238, 232, 233t
  - referrals, 246, 256-257, 302, 303t
  - refractory RLS, 245-252
  - rotating treatment, 255-256
  - See also *Daily RLS; Intermittent RLS; Refractory RLS*.
- pharmacologic treatment, 155-230
  - See also *Medications*.
- prophylactic treatment, 125
- resistance to. See *Refractory RLS*.
- special populations, 261-281
  - children, 266-267
  - elderly, 269-270
  - iron deficiency with or without anemia, 261-263
  - periodic limb movement disorder (PLMD), 272-274
  - pregnant and breast-feeding women, 267-269
  - secondary RLS, 261-265
  - surgery/outpatient procedures, 148-149, 270-272
  - uremia, 263-265
- tailoring to symptoms, 123-128
- timing of doses and, 124t
- treatment decisions
  - frequency and severity of symptoms, 126-127
  - general guide to, 124t
  - tailoring to symptoms, 123-128
  - timing of symptoms, 125-126
  - when to treat, 123-125, 124t
- See also *Management of RLS; Medications*.
- Triazolam, 211t, 213, 274
- Tricyclic antidepressants (TCAs), 43t, 137, 291-292
- Trimethobenzamide, 138
- Twin study, 56
  
- UARS (upper airway resistance syndrome), 44
- Upper airway resistance syndrome (UARS), 44
- Upper limb symptoms, 23-25

## Uremia, 263-265

- secondary RLS in (uremic RLS), 263-265
  - benzodiazepines for, 265
  - dopaminergic drugs for, 263-264
  - gabapentin for, 264
  - nonpharmacologic therapy for, 263
  - opioids for, 264-265
- Urge to move the legs (diagnostic feature), 22-26, 24t-25t
- URGES (five diagnostic features of RLS), 22-32, 24t-25t
  - Evening or night worse, 25t, 27-29
  - Gets better with (relieved by) movement, 25t, 27
  - questions to elucidate, 33t-34t
  - Rest induced, 25t, 26
  - Solely not accounted by another condition, 25t, 29-32, 31t-32t
  - Urge to move the legs, 22-26, 24t-25t

## Valproic acid, 188t, 199-200, 293

Varicose veins, as RLS mimic, 32t

Vascular disorders, as RLS mimics, 32t

Vitamins, 147, 215

B<sub>12</sub>, 215, 267

deficiency, 55t, 116

E, 215

Voluntary movement, component of RLS, 12

Web resources for RLS, 234, 319-320

WED (Willis-Ekbom Disease), 11-20, 301

See also *Restless Legs Syndrome (RLS)*.

Willis, Thomas, 11

description and treatment of RLS, 14

first documented drugs prescribed for RLS, 200

Willis-Ekbom Disease (WED), 11-20, 301

See also *Restless Legs Syndrome (RLS)*.

Women

prevalence and risk of RLS, 54, 55t, 56, 57t

prevalence of major depressive disorder, 284

Work issues

consequences of RLS, 16-17, 99-101

shift work, 100, 141-142

Worsening of symptoms. See *Symptoms, worsening of*.

Yoakum, Robert, 18

Zaleplon, 212t, 214

    pregnancy risk category, 269t

Zolpidem, 212t, 214-215

    pregnancy risk category, 269t

Zonisamide, 188t